U.S. FDA Approves Lower Dose Formulation of ANGELIQ® (Drospirenone and...
, Feb. 29, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a lower dose formulation of ANGELIQ® (drospirenone...
View ArticleFDA approves first nonhormonal drug for hot flashes
Published July 01, 2013The Wall Street Journal The Food and Drug Administration Friday approved the first nonhormonal drug designed to treat hot flashes, one of the most bothersome symptoms of...
View ArticleNOVEN PHARMACEUTICALS Quick Quote:
--> Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline 7/10/2007 Acquisition Offers Self-Supporting Marketing & Sales Infrastructure Plus...
View ArticleNoven To Acquire Jds Pharmaceuticals, Expanding Business Model & Broadening...
07/19/2007 04:55:27 PM EDT Women's Health Weekly 2007 JUL 26 - (NewsRx.com) -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that it has agreed to acquire JDS Pharmaceuticals, LLC for...
View ArticleNoven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening...
07/10/2007 02:00:18 AM EDT Business Wire Infrastructure Plus High-Potential Late-Stage Product Pipeline Pharmaceutical Writers/Business Editors MIAMI--(BUSINESS WIRE)----Noven Pharmaceuticals, Inc....
View ArticleNoven Reports Positive Phase 2 Results for Mesafem(TM) Non-Hormonal Therapy...
MIAMI, Jul 14, 2009 (BUSINESS WIRE) -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced positive top-line results from its Phase 2 clinical study evaluating Mesafem(TM) (low-dose paroxetine...
View ArticleNoven Completes Phase 3 Clinical Program for Investigational Non-Hormonal...
MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has completed the Phase 3 clinical...
View ArticleNoven Announces Phase 3 Results for Investigational Non-Hormonal Therapy for...
MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced top-line results from the first of two planned Phase...
View ArticleNotification of the Noven Pharmaceuticals, Inc. assigns rights for Brisdelle®...
(Source: Hisamitsu Pharmaceutical Co Ltd) Microsoft Word - Brisdelle Pexeva譲渡_EN版_Noven確認済_20160726 This material is an English translation of the press release announced on July 26, 2016 in Japanese,...
View Article
